Key Drivers
- Margin strength
- Cash conversion
- Premium valuation
AIAI Summary
BSX is no longer a straightforward medtech compounder; after the guidance cut and electrophysiology scrutiny, the stock now hinges on whether management can prove revenue growth is converting into earnings again, with FARAPULSE/WATCHMAN upside offset by execution and litigation risk that likely keeps the shares under pressure until credibility is rebuilt.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Cash conversion
- •Premium valuation
BSX shows strong profitability and cash generation with stable margins and improving liquidity, but elevated intangibles, moderate leverage, and a rich valuation limit the near-term appeal.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed rebounds
- •Oversold support
BSX has been in a clear downtrend over the last month, with repeated failed rebounds, support now near $52.5–$53.5, and a rebound setup only if it holds that low area and reclaims $56–$62.
Sharp decline from $65.69 to $52.68 with every rebound fading below the mid-$50s
Sentiment & News
Key News Insights:
- •Cardiovascular growth
- •Legal overhang
- •Valuation reset
BSX is benefiting from strong cardiovascular product momentum and analyst support, but lower guidance, margin pressure, and securities-fraud lawsuits may keep the stock volatile.
The news mix is moderately negative near term, with product strength partly offset by guidance cuts, litigation risk, and sustained share-price volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings